Recent News

• 05.18.2026 - Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
• 05.07.2026 - Krystal Biotech to Present at BofA Securities 2026 Health Care Conference
• 05.04.2026 - Krystal Biotech Announces First Quarter 2026 Financial and Operating Results
• 04.30.2026 - Krystal Biotech to Present at Upcoming Scientific Conferences
• 04.21.2026 - Krystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026

Recent Filings

• 05.04.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.04.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.04.2026 - EX-99.1 EX-99.1
• 05.04.2026 - 8-K Current report
• 04.29.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 04.03.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.03.2026 - DEF 14A Other definitive proxy statements
• 04.03.2026 - ARS Annual Report to Security Holders
• 03.27.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 03.06.2026 - 4 Statement of changes in beneficial ownership of securities